<p>Stemtech Corporation 宣佈與 Lightway Ventures 建立戰略合資企業，成立 Stemtech Asia (Hong Kong)，以在中國分銷其幹細胞營養產品。根據協議，Stemtech 將持有 51% 的股份，Lightway Ventures 持有 49%，利潤平分。該合資企業旨在通過 Lightway 的區域網絡在中國推廣 Stemtech 的抗衰老和健康產品，重點針對主要的電子商務和藥房渠道。Stemtech 計劃最終在當地生產產品，初步推出預計將在上海和北京等主要城市進行，具體取決於最終的資金和監管批准。免責聲明：本新聞簡報由 Public Technologies (PUBT) 使用生成性人工智能創建。雖然 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。Stemtech Corp. 於 2025 年 12 月 02 日通過 ACCESS Newswire (參考 ID: 1113656) 發佈了用於生成本新聞簡報的原始內容，並對此信息的準確性承擔全部責任。© 版權 2025 - Public Technologies (PUBT)</p>

STEK

<p>Stemtech 公司與 Lightway Ventures 成立了合資企業，進軍中國市場，設立了 Stemtech Asia（香港）以分銷幹細胞營養產品。Stemtech 持有 51% 的股份，Lightway Ventures 持有 49% 的股份，利潤均分。該合資企業瞄準主要的電子商務和藥房渠道，計劃在獲得資金和監管批准後，在上海和北京進行本地生產和初步推廣</p>

<p>Stemtech Corporation has announced a strategic joint venture with Lightway Ventures to establish Stemtech Asia (Hong Kong) for the distribution of its stem cell nutrition products in China. Under the agreement, Stemtech will hold a 51% stake and Lightway Ventures 49%, with profits split equally. The venture aims to introduce Stemtech’s anti-aging and wellness products across China, leveraging Lightway’s regional network and targeting major e-commerce and pharmacy channels. Stemtech plans to eventually manufacture products locally, with an initial rollout expected in key cities such as Shanghai and Beijing, pending final funding and regulatory approvals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stemtech Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1113656) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>
<div class="lb-trans"><p>Stemtech Corporation 宣佈與 Lightway Ventures 建立戰略合資企業，成立 Stemtech Asia (Hong Kong)，以在中國分銷其幹細胞營養產品。根據協議，Stemtech 將持有 51% 的股份，Lightway Ventures 持有 49%，利潤平分。該合資企業旨在通過 Lightway 的區域網絡在中國推廣 Stemtech 的抗衰老和健康產品，重點針對主要的電子商務和藥房渠道。Stemtech 計劃最終在當地生產產品，初步推出預計將在上海和北京等主要城市進行，具體取決於最終的資金和監管批准。免責聲明：本新聞簡報由 Public Technologies (PUBT) 使用生成性人工智能創建。雖然 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。Stemtech Corp. 於 2025 年 12 月 02 日通過 ACCESS Newswire (參考 ID: 1113656) 發佈了用於生成本新聞簡報的原始內容，並對此信息的準確性承擔全部責任。© 版權 2025 - Public Technologies (PUBT)</p>
</div>

Stemtech 公司與 Lightway Ventures 成立合資企業以進軍中國市場